【摘要】 目的评价重组人血小板生成素(rhTPO)治疗白血病化疗后血小板(PLT)减少症的疗效和安全性。方法 96例白血病患者随机分为治疗组(重组人血小板生成素,rhTPO)与对照组(重组人白介素-11,rhIL-11),分别皮下注射,观察外周血小板的变化。结果治疗组血小板的最低值和恢复的最高值显著高于对照组;治疗组的PLT<50×109L-1的持续时间、恢复到70×109L-1和125×109L-1所需要的时间,显著低于对照组所需时间;治疗组不良反应少且较轻微。结论重组人血小板生成素(rhTPO)治疗急性白血病化疗后的血小板减少症疗效显著且安全性好。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of recombinant human thrombopoietin( rhTPO) compared with recombinant human interleukin 11( rhIL-11) in the treatment of chemotherapy induced thrombocytopenia in patients with leukemia. Methods Ninety-six patients with leukemia were divided into trial and control groups randomly. Patients in trial group were given rhTPO subcutaneously and patients in control group were given rhIL-11 subcutaneously. The peripheral platelet count was observed consecutively. Results The mean minimal and maxima platelet count in the trial group was significantly higher than the control group. The time of platelet count less than 50 × 109L-1and needed to achieve a level to 70 × 109L-1and 125 × 109L-1in the trial group were significantly shorter than in the control group. Slight adverse reaction was observed in the trial group. Conclusions rhTPO is effective and safety in treatment of acute leukemia chemotherapy induced thrombocytopenia.更多还原